Constantin Dreher1, Tristan Anselm Kuder2, Stefan Windhaber1, Franziska König1, Daniel Paech1, Anoshirwan Tavakoli1, Regula Gnirs1, Thomas Benkert3, Heinz-Peter Schlemmer1, and Sebastian Bickelhaupt1
1Radiology, German Cancer Research Center, Heidelberg, Germany, 2Medical Physics in Radiology, German Cancer Research Center, Heidelberg, Germany, 3Siemens Healthcare GmbH, Erlangen, Germany
Synopsis
In
oncological, abdominal MRI, the value of motion corrected Diffusion-Weighted Imaging
(DWI) including complex averaging with high and ultra-high b-values remains to
be defined. This is of special importance regarding the balance between normal
tissue suppression and suspicious lesion demarcation. This prospective study investigated
41 patients with an oncologically optimized prototype-DWI (with complex
averaging, motion correction between averages, rescaling of motion corrupted
averages, background suppression). Image quality, tissue differentiation and
lesion detection/characterization were significantly increased in high (b900)
as compared to ultra-high (b1500) DWI. At the same time, apparent signal-intensity
ratio of lesion/normal tissue was not significantly different.
Introduction
Diffusion-Weighted Imaging (DWI) is of high diagnostic importance in
the setting of oncological magnetic resonance imaging (MRI) follow-up
examinations. However, DW-MRI is challenged by motion artifacts and little SNR
in the retroperitoneum, which is why it has to be optimized [1, 2]. Current developments allow using adapted DWI sequences with
improved motion
correction between the averages and complex averaging modifications. However,
in comparison to DW-MRI of the prostate [3], the influence on the balance of
normal tissue suppression and lesion demarcation of suspicious findings in
high- and ultra-high b-value DWI remains unclear. The
target of this study is therefore to prospectively evaluate an oncologically
optimized DWI sequence with improved motion correction between the averages and complex averaging in abdominal MRI for both its general image quality and potential in
the presentation of malignant lesions by the use of high and ultra-high b-values.Methods
This IRB-approved, prospective study
included 41 prospectively acquired oncological MRI examinations (mean age: 57
years; male/female: 16/25) of the abdomen, by the use of a 1.5T MRI scanner
(MAGNETOM Aera, Siemens Healthcare GmbH, Germany) with a prototypical EPI DWI
sequence (b=0,50,900,1500s/mm²), including complex averaging, motion correction
between the averages, rescaling of motion corrupted averages, and background
suppression.
The following parameters were used:
TR=7.9 s; TE=57 ms; FOV 480x270 mm²; matrix 164x92; resolution 3x3 mm²,
interpolated to 1.5x1.5 mm²; slice thickness 5 mm; bandwidth 2540 Hz/Px;
b-values 0, 50, 900, 1500 s/mm² (1, 1, 16 and 18 averages); gradient mode
3D-diagonal; 90 slices in 3 steps, 15 min.
High b-value DWI with b900 (s/mm²)
and ultra-high b-value DWI with b1500 (s/mm²) were compared as follows:
Both normal tissue image quality,
tissue differentiation parameters and diagnostic confidence for
characterization and detection of malignant lesions were rated by two
independent, blinded readers using a 5-point Likert Scale [4]. The apparent signal intensities of the
malignant lesions and the normal tissue of the same organ were divided,
resulting in lesion-to-normal-tissue ratio (LNTR). Statistics included
Wilcoxon-signed-rank test and kappa statistic for interreader agreement
analysis (p<0.05).Results
Image quality parameters (contour
sharpness right liver, left liver and pancreas) and tissue differentiation for
upper abdominal organs and retroperitoneal structures were significantly higher
with b900 as compared to b1500 optimized DWI (Figure 1 and 2) (p<0.001).
Interreader reliability test showed good agreement (kappa=0.715) (p<0.001).
Thirty-seven suspicious lesions were
detected (12 lymphatic, 8 hepatopancreatic and 17 lesions of other origins).
Reader confidence for characterization/detection of malignant lesions was
significantly higher using the b900 (mean: 4.4±0.6) as
compared to the b1500 optimized DWI (mean: 4.0±0.8) (p=0.001) with an overall good interreader agreement (kappa=0.723)
(p<0.001). The increased confidence of lesion recognition on b900 remained
significant in subgroup analysis of lymphatic lesions (p=0.003), but not with
regard to hepatopancreatic and lesions of other origins (p=0.102, 0.317)
(Figure 1 and 3).
Apparent-LNTR of b900 vs. b1500
optimized DWI was not significantly different with regard to all lesions (mean:
3.0±2.3 vs. 2.7±2.2, p=0.067), and the subgroup analysis of lymphatic (mean:
2.2±1.0 vs. 2.0±1.5, p=0.117), hepatopancreatic (mean: 1.8±0.5 vs. 1.8±0.8,
p=0.944) and lesions of other origins (mean: 4.1±2.9 vs. 3.7±2.8, p=0.148).Discussion
This study
evaluated the applicability of an adapted DWI sequence in oncologic follow-up
examinations using improved motion correction between the averages and complex
averaging modification with high- and ultra-high b-values for improved image
quality and lesion detection. The findings demonstrated that high b-value
provided an improved image quality and lesion conspicuity as compared to
ultra-high b-value DWI. These findings were significant with regard to image
quality, while at the same time ultra-high b-value DWI was inferior to high
b-value DWI concerning the reader confidence of lesion detection and
characterization. Consequently, the potential and usage of ultra-high vs. high
b-values in oncological examinations of the abdominal region should be
critically evaluated in future studies. However, this does not imply any
statement about quantitative DWI analysis (e.g. ADC).Conclusion
This prospective study demonstrates the
feasibility of a novel approach of oncologically optimized DWI with improved motion
correction between the averages and complex averaging modification in
oncological follow-up MRI examinations. The results demonstrated that high
b-value DWI (b=900s/mm²) provided better image quality and lesion conspicuity
as compared to ultra-high b-values (b=1500s/mm²) and might be preferred for
oncologic follow-up abdominal MRI examinations.Acknowledgements
Special acknowledgments and thanks to Siemens
Healthineers for providing the optimized protoype sequence and protocolReferences
1. Taron, J., et al., Clinical Robustness of Accelerated and
Optimized Abdominal Diffusion-Weighted Imaging. Invest Radiol, 2017. 52(10): p. 590-595.
2. Zhang, T.T., et
al., Differentiation of pancreatic
carcinoma and mass-forming focal pancreatitis: qualitative and quantitative
assessment by dynamic contrast-enhanced MRI combined with diffusion-weighted
imaging. Oncotarget, 2017. 8(1):
p. 1744-1759.
3. Ueno, Y., et al.,
Ultra-high b-value diffusion-weighted MRI
for the detection of prostate cancer with 3-T MRI. J Magn Reson Imaging,
2013. 38(1): p. 154-60.
4. de Winter,
J.C.F., Dodou, D., Five-point Likert items:
T test versus Mann–Whitney–Wilcoxon. Practical Assessment, Research &
Evaluation, 2010. 15(11): p. 16.